bluebird bio to split into oncology and gene therapy specialists
pharmaphorum
JANUARY 11, 2021
That made things difficult for development partner Bristol-Myers Squibb , which inherited the drug previously known as bb2121 through its acquisition of Celgene late in 2019. million price tag. The FDA is now due to make a decision on ide-cel as a treatment for multiple myeloma in late March.
65 
Let's personalize your content